Screener
Kyverna Therapeutics, Inc. KYTX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 2,327 | 2,825 |
| Interest expense | (667) | (25) |
| Other expense, net | (21) | (27) |
| Total other income, net | 1,639 | 2,773 |
| Net loss | (39,728) | (44,635) |
| Other comprehensive loss | ||
| Unrealized loss on available-for-sale marketable securities, net | (193) | (106) |
| Total other comprehensive loss | (193) | (106) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s other income (expense)?
- Kyverna Therapeutics, Inc. (KYTX) reported other income (expense) of $1.64M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s other income (expense) changed year-over-year?
- Kyverna Therapeutics, Inc.'s other income (expense) decreased by 40.9% year-over-year, from $2.77M to $1.64M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s other income (expense)?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s other income (expense) has grown at a 104.4% compound annual growth rate (CAGR), from $2.04M to $8.52M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Kyverna Therapeutics, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude